Abstract
Oral third-generation cephalosporins (3GCs) are not recommended for use owing to their low bioavailability and the risk of emergence of resistant microorganisms with overuse. A standardized and effective method for reducing their use is lacking. Here, in a 60-month, single-institution, interrupted time-series analysis, which was retrospectively conducted between April 1, 2017, and March 31, 2022, we evaluated the effectiveness of a four-phase intervention to reduce the use of 3GCs in patients at a cancer center: Phase 1 (pre-intervention), Phase 2 (review of clinical pathways), Phase 3 (establishment of infectious disease consultation service and implementation of antimicrobial stewardship program), and Phase 4 (educational lecture and pop-up displays for oral antimicrobials at the time of ordering). Although no significant changes were observed in Phases 3 and 4, the first intervention resulted in a significant decrease in the trend and level of days of therapy (DOT) for 3GCs. The level for cephalexin DOT and the trend for sulfamethoxazole-trimethoprim DOT increased in Phase 4, and the trend for amoxicillin and amoxicillin-clavulanate DOT increased in Phase 3. Macrolide DOT showed a decreasing trend in Phases 2 and 4 and decreasing and increased levels in Phases 3 and 4, respectively; no change was observed for quinolones. Actual and adjusted purchase costs of 3GCs decreased significantly during all study periods, while those for oral antimicrobials decreased in Phase 2, and actual purchase costs increased in Phases 3 and 4. No significant reduction in resistant organisms, length of hospital stay, or mortality was observed. This is the first study on the effects of oral 3GC reduction strategies in patients with cancer. We conclude that even facilities that substantially use antimicrobials can efficiently reduce the use of 3GCs.
Funder
JSPS KAKENHI
Aichi Cancer Research Foundation
Publisher
Public Library of Science (PLoS)
Reference34 articles.
1. World Health Organization Global Action Plan on Antimicrobial Resistance, 2015 [cited 2021 December 25]. Available from: https://www.who.int/antimicrobial-resistance/global-action-plan/en/
2. The Government of Japan NAP on Antimicrobial Resistance (AMR) 2016–2020 [cited 2021 December 25]. Available from: https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000138942.pdf.
3. Effects of infectious disease consultation and antimicrobial stewardship program at a Japanese cancer center: An interrupted time-series analysis;N Itoh;PLOS ONE,2022
4. Infectious disease specialist consultations in a Japanese cancer center: A retrospective review of 776 cases;N Itoh;BMC Health Serv Res,2020
5. Pulmonary infections mimicking malignancy on bronchoscopy: A retrospective single-center study in Japan;N Itoh;J Gen Fam Med,2020